Skip to main navigation
Skip to search
Skip to main content
Elsevier's Research Collaborations Home
Help & FAQ
Home
Profiles
Partnerships
Projects
Research output
Datasets
Prizes
Activities
Press/Media
Search by expertise, name or affiliation
RPSGL-Ig for improvement of early liver allograft function: A double-blind, placebo-controlled, single-center phase II study
R. W. Busuttil
, G. S. Lipshutz
, J. W. Kupiec-Weglinski
, S. Ponthieux
, D. W. Gjertson
,
C. Cheadle
, T. Watkins
, E. Ehrlich
, E. Katz
, E. C. Squiers
, H. Rabb
, S. Hemmerich
Research output
:
Contribution to journal
›
Article
›
peer-review
67
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'RPSGL-Ig for improvement of early liver allograft function: A double-blind, placebo-controlled, single-center phase II study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
6-month Follow-up
25%
Allograft
25%
Aspartate Aminotransferase
25%
Deceased Donor Liver Transplantation
25%
Donor Risk Index
25%
Early Graft Failure
50%
Hepatic Ischemia-reperfusion Injury
25%
Injury Biomarkers
50%
IP-10
25%
Liver Allograft Function
100%
Liver Enzymes
25%
Per-protocol
25%
Phase II Study
100%
Pretransplant
25%
Serum Transaminase
25%
Systemic Dose
25%
Therapeutic Modulation
25%
Transplantation
25%
Pharmacology, Toxicology and Pharmaceutical Science
Aminotransferase
50%
Aspartate Aminotransferase
25%
Bilirubin
75%
Cytoprotective Agent
25%
Liver Enzyme
25%
Liver Ischemia
25%
Selectin (Glycoprotein)
100%
Selectin Antagonist
25%